Day One Wednesday May 5, 2021 Day Two Thursday May 6, 2021 8:15 am Virtual Coffee Room Opens 8:45 am Chair’s Opening Remarks Lawrence Lamb EVP & CSO, In8Bbio Targeting Solid Tumors with Combination Approaches 9:00 am Harnessing the Next Wave of Immune Checkpoints to Enhance Cell Therapy in Solid Tumors Marc Van Dijk CTO, AgenTus Therapeutics 9:30 am Leveraging Immune-Adjuvants to Enhance T Cell Therapy in Solid Tumors 10:00 am Understanding the Solid Tumor Microenvironment to Devise Multi-Targeting Strategies Jakob Dupont EVP, Head of Global Research & Development, Atara Biotherapeutics 10:30 am Morning Refreshments & Speed Networking Harnessing Natural Immune Biology to Inform Multi-Targeted Strategies 11:00 am Targeting the Solid Tumor Microenvironment with Synergistic Therapy to Enhance T Cell Infiltration and Survival Francesco Marincola CSO, Refuge Biotech 11:30 am Leveraging TILs to Engage Solid Tumors as a Natural Multi-Targeted Approach Madan Jagasia SVP Medical Affairs, Iovance Biotherapeutics Inc. 11:50 am CRISPR/Cas9 Engineered TIL for Supercharged T Cell Function Micah Benson VP, Head of Immunobiology, KSQ Therapeutics 12:10 pm Expert Panel Q&A: Challenges, Strengths and Next Steps in Advancing TIL Therapies Madan Jagasia SVP Medical Affairs, Iovance Biotherapeutics Inc. Micah Benson VP, Head of Immunobiology, KSQ Therapeutics 12:30 pm Lunch & Networking Leveraging Logic to Enhance Tumor-Specificity 1:30 pm Developing Engineering Solutions to Promote Tumor-Targeting, and Function in the Tumor Microenvironment Melita Irving Group Leader, Ludwig Institute for Cancer Research Lausanne 2:00 pm Developing Co-Stimulatory Domains to Create Robust, Target Cell-Specific Activation Marco Ruella Assistant Professor of Medicine, University of Pennsylvania 2:30 pm Advancing Target Identification to Identify Novel, Clinically Relevant Targets Quickly Hanspeter Gerber CSO, 3T Biosciences 3:00 pm Afternoon Poster Session & Networking Tuned Tumor Killing with Synergistic Therapy 3:30 pm Targeting Multiple Antigens with Antibody-Redirected CARs Sequentially vs. Simultaneously Travis Young VP Biologics, Calibr at Scripps Research 4:00 pm Personalized Adoptive TCR-T Cell Therapies Targeting Neoantigens for the Treatment of Solid Tumors Barbara Sennino Director, Tumor Immunology, PACT Pharma 4:00 pm Employing Viral Combinations to Make Solid Tumors Vulnerable to CAR-T Therapy Saul Priceman Principal Investigator, City of Hope 4:30 pm Suppressing the Tumor Microenvironment with Combination Therapy to Enhance Anti-Tumor Efficacy in Solid Tumor Indications 5:00 pm Chair’s Closing Remarks Lawrence Lamb EVP & CSO, In8Bbio 5:15 pm Close of Summit